AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
02 janv. 2020 16h53 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
19 déc. 2019 08h25 HE
|
Asklepios BioPharmaceutical, Inc.
– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
25 avr. 2018 08h05 HE
|
Asklepios BioPharmaceutical, Inc.
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE...